Meaningful efficacy observed in slow-progressor subgroup; NfL biomarker improvements support potential for accelerated regulatory pathway SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- ...

Neuronata-R®, an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS), ...

Discover how stem cells may help reduce acne scars by boosting collagen, improving skin texture, and speeding up healing—plus ...

Parkinson’s disease is a neurodegenerative disorder that causes a gradual loss of brain nerve cells, which produce a chemical ...

Researchers at the Abu Dhabi Stem Cells Centre are hopeful of a breakthrough in their work on a cure for Type 1 diabetes “in ...

Stem cells from donated placentas appear safe and may help ease secondary progressive MS, a small open-label Phase 1 clinical ...

The Global Stem Cell Therapy Market is set to witness a healthy growth rate of 20% by 2029. A favorable investment ...

The FDA has granted Mesoblast’s stem cell therapy, Ryoncil (remestemcel-L), seven years of orphan drug exclusivity for the ...

Patients given Neuronata-R who progressed more slowly saw significant gains in CAFS, slower declines in ALSFRS-R scores, and ...

Investors now have three ASX-listed stem cell therapy companies to choose from – and we can thank Mesoblast for inspiring the third.

Tumor microenvironment (TME) plays a pivotal role in malignant progression and metastatization in several tumors, including ...